



Technical Report No. 85

Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers



Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers Team

Authors

Core Team

Tia Bush, Amgen (Chair)
John Ayres, MD, Pharma Safety Solutions
Cecile Begat, Bayer
Antonio Burazer, Takeda
Fran DeGrazio, West Pharmaceutical Services
Carol Flynn, MEng, Corning
Abizer Harianawala, Stevanato Group
Paul Kinsey, GSK
Jahanvi Miller, MBA, PDA

Anthony Perry, Schott
John Shabushnig, Ph.D., Insight Pharma Consulting
Xu Song, MEng, Astra Zeneca
Hervé Soukiassian, MEng, BD
Andrew Spasoff, MS, Astra Zeneca
Amy Stanton, Amgen
Dorothee Streich, Ph.D., Bayer
Rick Watson, Merck

Elastomer Subteam

Ravi Patel, West Pharmaceutical Services (Co-Chair)
John Rech, West Pharmaceutical Services (Co-Chair)
Andrea DeSalvia, Aptar
Wadi Farach, MEng, Amgen

Gert Gregoire, MBA, Datwyler
Lucia Ino, West Pharmaceutical Services
Denise Schnaufer, Merck
Larry Staub, MS, Quality Advisor
Julie Suman, Next Breath
Rick Watson, Merck

Glass Subteam

Hervé Soukiassian, MEng, BD (Co-Chair)
Paul Kinsey, GSK (Co-Chair)
Alfred Breunig, Nipro Pharma Packaging
Benjamin Coutan, MBA, Gerresheimer
Wadi Farach, MEng, Amgen
Carol Flynn, MEng, Corning Incorporated

Martina Marchioro, Stevanato Group
Didier Morel, BD
Anthony Perry, Schott
Volker Rupertus, Schott AG
Daniele Zuccato, Schott AG

Contributors

Jean Bernard Theo, BMS
Buffy Hudson-Curtis, PhD, GSK
Swen Maas, Material Analytischer Service

Abriana Rozentsvayg, MS, Pfizer
Christian Schwarz, Amgen
Linda Wildling, PhD, Takeda

Acknowledgements

The authors wish to thank the Pharmaceutical Manufacturers Forum (PMF) for their encouragement and support in development of these studies. We wish to further thank the following companies for their participation in the studies documented herein: Amgen Inc., Aptar, Bayer AG, BD, Bristol Myers Squibb, Corning Inc, Datwyler, Gerresheimer AG, GlaxoSmithKline, Material Analytischer Service, Nipro Pharma Packaging, Stevanato Group, Schott, Takeda, and West Pharmaceutical Services.

Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers

Technical Report No. 85

ISBN: 978-1-945584-26-8
© 2021 Parenteral Drug Association, Inc.
All rights reserved.



Table of Contents

| | | | |
|---|----------|---|-----------|
| 1.0 INTRODUCTION | 1 | 5.0 GLASS CONTAINER INSPECTION METHOD..... | 11 |
| 1.1 Purpose | 1 | 5.1 Inspection of Ready-to-Use Empty Glass | |
| 1.2 Scope | 1 | Containers | 11 |
| 2.0 GLOSSARY AND ABBREVIATIONS..... | 2 | 5.1.1 Operator Training for the Enhanced | |
| 2.1 Abbreviations..... | 3 | Container Inspection Method..... | 12 |
| 3.0 CURRENT STATE OF VISUAL INSPECTION FOR | | 5.1.2 Equipment and Setup | 12 |
| PARTICLES..... | 3 | 5.1.3 Magnification Requirements To Inspect Glass | |
| 3.1 Patient Risk Assessment..... | 4 | Containers..... | 14 |
| 3.2 Existing Test Methods and Limitations | 5 | 5.1.4 Glass Container Inspection Procedure | 14 |
| 3.2.1 ISO Test Method 8871-3 | 6 | 5.2 Method Qualification Strategy and Detection | 15 |
| 3.2.2 U.S. Pharmacopeia Methods | 6 | 5.3 Study Design | 17 |
| 3.2.3 European Pharmacopeia Methods | 7 | 5.3.1 Normalizing the Particle Size | 18 |
| 3.2.4 Japanese Pharmacopeia Methods..... | 7 | | |
| 3.3 Conclusion..... | 7 | | |
| 4.0 ELASTOMERIC CLOSURES TEST METHOD | 8 | 6.0 CONCLUSION | 19 |
| 4.1 Enhanced Closures Testing Method Development | 8 | 7.0 REFERENCES..... | 20 |
| 4.1.1 Size Threshold | 8 | | |
| 4.1.2 Novel Particle Size Measurement Tool | 10 | 8.0 APPENDICES..... | 21 |
| 4.2 Summary for Performing the Enhanced Closures | | 8.1 Appendix A. Additional Information on Enhanced | |
| Testing Method | 10 | Closures Testing Method Development..... | 21 |
| 4.3 Method Qualification Strategy and Lessons | | 8.2 Appendix B. Method: Determination of Visible | |
| Learned..... | 11 | Particles and Fibers on Elastomeric Components by | |
| | | Membrane Filtration and Microscopic Examination | 34 |
| | | 8.3 Appendix C. Additional Information on Empty | |
| | | Glass Inspection Capability Studies | 36 |
| | | 8.4 Appendix D. Method: Visual Inspection of Empty | |
| | | Glass Containers | 44 |

FIGURES AND TABLES INDEX

| | | | |
|---|----|--|----|
| Figure 3.0-1 FDA Recall Notices For Injectable Products, Years 2010-2019..... | 3 | Figure 5.1.2-3 Placement Of Container Within The Inspection Hood During Inspection..... | 14 |
| Figure 3.0-2 FDA Recall Notices For Particles In Injectable Products, Years 2010-2019..... | 4 | Figure 5.2-1 Locations Where Particles Were Seeded Into Or Onto Containers (Vials, Cartridges, And Syringes) In Prepared Test Kits | 15 |
| Table 3.2.2-1 Inspection Conditions and Acceptance Criteria for Visible Particles Found in the USP, EP, and JP..... | 7 | Table 5.2-1 Summary of Nominal Particle Size by Material | 16 |
| Table 4.1.1-1 Threshold Value to Use when Classifying Particles as Visible or Subvisible (by methods more sensitive as compared to the unaided eye)..... | 9 | Table 5.2-2 Measurement Method Used to Determine Nominal Particle Size | 16 |
| Figure 4.1.2-1 Microscope Reticle Design For Elastomer Component Particle Analysis | 10 | Figure 5.2-2 Examples of Feret Max And Rect A And B Particle Size Measurements | 17 |
| Table 5.1-1 Key Attributes of Proposed Inspection Conditions and Method | 12 | Figure 5.3-1 Probability Of Detection For Particles And Fibers Of Varying Size During Inspection Of Empty Glass Containers..... | 17 |
| Figure 5.1.2-1 Visual Inspection Workstation..... | 13 | Figure 5.3.1-1 Probability Of Detection For Particles And Fibers Of Varying Size During Inspection Of Empty Glass Containers With Size Normalized To Apparent Area..... | 18 |
| Figure 5.1.2-2 Example Of Container Inspection Using Recommended Method And Relative Placement In The Inspection Hood..... | 13 | | |

| | | |
|-------------------|--|----|
| Figure A1 | Process Map of the Pilot (method development) and Qualification Strategy .. | 22 |
| Figure A2 | Method Qualification Sample Generation Stratification | 23 |
| Figure A3 | Process Map of Final Method Qualification Study | 24 |
| Figure A4 | Interval plot of Supplier 1 results for particles >100 μm for each operator | 25 |
| Figure A5 | Interval plot of replicate inspection results for Supplier 1, Operators 1 vs 3 and Operator 2 vs 3, for particles >100 μm | 25 |
| Figure A6 | Interval plot of Supplier 1 results for particles >300 μm for each operator | 26 |
| Figure A7 | Interval plot of replicate inspection results for Supplier 1, Operators 1 vs 3 & Operators 2 vs 3, for fibers >300 μm | 26 |
| Figure A8 | Interval plot of Supplier 2 results for particles >100 μm for each operator | 27 |
| Figure A9 | Interval plot of Supplier 2 group performance for particles >100 μm | 27 |
| Figure A10 | Interval plot of Supplier 2 results for fibers >300 μm for each operator | 28 |
| Figure A11 | Interval plot of Supplier 2 group performance for fibers >300 μm | 28 |
| Figure A12 | Interval plot of Supplier 3 results for particles >100 μm for each operator | 29 |
| Figure A13 | Interval plot of Supplier 3 group performance for particles >100 μm | 29 |
| Figure A14 | Interval plot of Supplier 3 results for fibers >300 μm for each operator | 30 |
| Figure A15 | Interval plot of Supplier 3 group performance for fibers >300 μm | 30 |
| Figure A16 | Comparison of inspection performance by both supplier and operator for particles >100 μm | 31 |
| Figure A17 | Box plot of performance by supplier for particles >100 μm | 32 |
| Figure A18 | Comparison of inspection performance by both supplier and operator for fibers >300 μm | 32 |
| Figure A19 | Box plot of performance by supplier for fibers >300 μm | 33 |
| Table B1 | Orbital Shaker RPM Ranges..... | 34 |
| Figure B1 | Flowchart showing the use of the specified reticle to determine status of any observed particles on the filter..... | 37 |
| Table C1 | Summary of Nominal Particle Size by Material | 38 |
| Figure C1 | Shape factor vs size for the particles and fibers seeded into test vials..... | 38 |
| Figure C2 | Graphic comparison of test kit composition (kits A, B, and C) | 39 |
| Figure C3 | Distribution of time required to complete inspection of test kit | 40 |
| Figure C4 | Particle inspection results with inspectors having prior experience with empty containers (Yes) and those without such experience (No) | 40 |
| Figure C5 | Fiber inspection results with inspectors having both prior experience (Yes) with empty containers and those without such experience (No) | 41 |
| Figure C6 | Probability of detection for particles of differing type and size | 41 |
| Figure C7 | Probability of detection for fibers of differing type and size | 42 |
| Figure C8 | Probability of detection for particles in various container types and sizes..... | 42 |
| Figure C9 | Probability of detection for fibers in various container types and sizes | 43 |
| Figure C10 | Boruta Plot of inspection study results demonstrating factors significant to reliable inspection performance..... | 43 |



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org